Comparison of Saliva and Mid-Turbinate Swabs for Detection of COVID-19

Jianyu Lai, B.Med., M.P.H.[a,b], Jennifer German, Ph.D.[b], Filbert Hong, Ph.D.[b], S.-H. Sheldon Tai, Ph.D.[b], Kathleen M. McPhaul, Ph.D., M.P.H.[b], Donald K. Milton, M.D., Dr.P.H.[b] for the University of Maryland StopCOVID Research Group[*]

[a] Department of Epidemiology and Biostatistics, University of Maryland School of Public Health, College Park, Maryland, USA
[b] Public Health Aerobiology and Biomarker Laboratory, Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park, Maryland, USA

[*] Dr. Donald K. Milton, University of Maryland School of Public Health, 4200 Valley Drive, College Park, MD 20742 email: dmilton@umd.edu; phone: 301-405-0389 (Alternate: Dr. Filbert Hong, at the same address, email fhong@umd.edu, phone: 301-405-4081)

Running Title: Saliva Versus MTS for COVID-19 Detection

Key Points:
- Saliva is more sensitive in detecting symptomatic cases of COVID-19 than MTS early in the course of infection.
- Saliva performs best in the pre-symptomatic period.
- Saliva and MTS demonstrated high agreement making saliva a suitable and cost-effective COVID-19 screening tool.

Abstract

Background: Saliva is an attractive sample for detecting SARS-CoV-2 because it is easy to collect and minimally invasive. However, contradictory reports exist concerning the sensitivity of saliva versus nasal swabs.

Methods: We recruited and followed close contacts of COVID-19 cases for up to 14 days from their last exposure and collected self-reported symptoms, mid-turbinate swabs (MTS) and saliva every two or three days. Ct values and frequency of viral detection by MTS and saliva were compared. Logistic regression was used to estimate the probability of detection by days since symptom onset for the two sample types.

Results: We enrolled 58 contacts who provided a total of 200 saliva and MTS sample pairs; 14 contacts (13 with symptoms) had one or more positive samples. Overall, saliva and MTS had similar rates of viral detection (p=0.78). Although Ct values for saliva were significantly greater than for MTS (p=0.014), Cohen's Kappa demonstrated substantial agreement (κ=0.83). However, sensitivity varied significantly with time relative to symptom onset. Early in the course of infection (days -3 to 2), saliva had 12 times (95%CI: 1.2, 130) greater likelihood of detecting viral RNA compared to MTS. After day 2, there was a non-significant trend to greater sensitivity using MTS samples.

Conclusion: Saliva and MTS specimens demonstrated high agreement, making saliva a suitable alternative to MTS nasal swabs for COVID-19 detection. Furthermore, saliva was more sensitive than MTS early in the course of infection, suggesting that it may be a superior and cost-effective screening tool for COVID-19.

Introduction

The U.S. Centers for Disease Control and Prevention (CDC) recommend the use of upper respiratory specimens, including but not limited to nasopharyngeal, mid-turbinate nasal, anterior nasal and saliva specimens for the initial diagnosis of COVID-19 [1]. Although nasopharyngeal swabs (NPS) are considered to be the standard for the detection of COVID-19 by most researchers, collection requires the use of trained professionals, can cause discomfort to the patients, and may pose greater risks to healthcare workers during sample collection [1–4]. Mid-turbinate swabs (MTS) are sometimes used as an alternative to NPS in an effort to reduce patient discomfort and occupational exposures to healthcare workers [4–6]. Compared to swab-based collection, saliva is even less invasive, more affordable, and can be self-collected with minimal or no supervision [1,7,8].

Existing studies focusing on the sensitivity of NPS compared to MTS, and NPS compared to saliva have produced contradictory results [2,4,9–11]. Few studies directly compare saliva and MTS specimens. Previous studies demonstrated that pre-symptomatic transmission results in higher secondary attack rates for both symptomatic and asymptomatic transmission [12,13]. However, most of the existing studies only looked at detection of symptomatic cases after symptom onset [2,4,9,10] and few looked at detection sensitivity starting with the pre-symptomatic period. Therefore, a study that conducts a direct comparison of MTS and saliva, including an assessment of sensitivity over time (starting during the pre-symptomatic period) is critical to identifying optimally sensitive methods for early detection and effective control of SARS-CoV-2 transmission.

The purpose of this study was to compare the sensitivity of MTS and saliva specimens for detecting SARS-CoV-2 by actively following close contacts of COVID-19 cases and collecting MTS and saliva samples for real-time reverse transcription polymerase chain reaction (RT-PCR) during their post-exposure quarantine period.

Methods

Study population

We analyzed MTS and saliva sample data from individuals who reported close contact with confirmed COVID-19 cases as part of the University of Maryland StopCOVID study [14] from May 2020 to April 2021.

Questionnaire and sample collection

Participants were followed every two or three days for up to 14 days from their last exposure or until SARS-CoV-2 was detected in their samples. If one or more of their screening samples became positive, results were confirmed by an appropriate clinical diagnostic test and they were recruited to participate in the exhaled breath aspect of the study that also involved the collection of saliva and MTS [14]. On each day of sample collection, participants answered an online questionnaire to update their current symptoms and medications. For those who reported having any symptom, they also reported their symptom onset date (i.e., "When did you begin to feel sick?").

The symptoms checklist in the baseline and follow-up questionnaires, as previously described [14], included runny nose, stuffy nose, sneezing, sore throat, earache, malaise, headache, muscle

101 and/or joint ache, sweat/feverish/chills, nausea, loss of appetite, vomiting, abdominal pain or
102 diarrhea, chest tightness, shortness of breath, and cough. Participants self-reported for each of
103 these 16 symptoms on a scale of 0 to 3 (0 = "no symptoms," 1 = "just noticeable," 2 = "clearly
104 bothersome from time to time, but didn't stop me from participating in activities," 3 = "quite
105 bothersome most or all of the time and stopped me from participating in activities").
106
107 For saliva collection, participants were instructed to not eat or drink 30 minutes prior to the visit
108 and then collect approximately 0.5-1 mL of saliva drooled into a plastic collection tube. For
109 MTS collection, trained clinical staff inserted a mid-turbinate swab approximately 1.5-2 inches
110 into one of the participants' nostrils, rotated once, and then withdrawn. This procedure was
111 repeated in the other nostril for a total of two MTS per participant per visit.
112

Laboratory analyses
Saliva samples were processed using the SalivaDirect method [8] as previously described [14].
Briefly, 50 µL of individual saliva samples were treated with Proteinase K (New England
Biolabs), heated at 95°C for 5 minutes, and kept at 4°C. MTS from both nostrils were combined
and processed as previously described [14]. Briefly, total nucleic acid was extracted from 200 µL
of MTS with MagMax Pathogen RNA/DNA Kit (Applied Biosystems) on KingFisher Duo Prime
(Thermo Fisher Scientific), following the manufacturers' protocols. The sample was eluted in 50
µL of Elution Buffer and kept at 4 °C. MS2 phage was spiked in each heat-treated saliva sample
and extraction to control for extraction and PCR failure. RT-PCR was set up on the same day;
each reaction consisted of 1X TaqPath 1-Step Master Mix, No ROX, 1X TaqPath COVID-19
Real Time PCR Assay Multiplex (both from Thermo Fisher Scientific), and 10 µL of heat-
treated saliva or eluted nucleic acids. Each PCR plate contained a positive control provided in the
TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific) and a no template control. A positive
sample was defined as having Ct (cycle threshold) values < 40 for at least two out of three
SARS-CoV-2 targets (ORF1ab, N gene, and S gene)[15]. The average Ct values of all positive
targets were used in the following analyses.
129

Statistical analyses
We analyzed only paired same-day saliva and MTS samples to ensure the comparability of the
two samples. Group comparisons were made between participants having a positive result for
either sample and those with both samples being negative. Continuous variables (age and BMI)
were compared using t-test, and categorical variables were compared using Chi-square test (sex
and chronic respiratory illness) and Fisher's exact test (age group, race, and ever smoker).
136
137 To compare the Ct values from saliva and MTS, we conducted paired t-test and Bland-Altman
138 analysis, and calculated the coefficient of determination (i.e., R squared from linear regression)
139 and Pearson correlation coefficient. The Chi-square test was used to explore the relationship
140 between detection and sample types. Cohen's Kappa was calculated to demonstrate the degree of
141 agreement between the two sample types.
142
For participants with a positive saliva or MTS sample, we used a generalized additive logistic
model [16] to estimate and plot the probability of having a positive result by days since symptom
onset for the two sample types. We also created a plot using the LOESS (locally weighted
smoothing) method with 95% confidence interval for the change of Ct values by days since

symptom onset for the two sample types. Logistic regression was used to estimate the relative
odds of detection of SARS-CoV-2 in saliva over specified intervals since symptom onset.
149
150 All the analyses were carried out using RStudio and R (version 4.0.4) [17].
151
152 *Ethics statement*
153 This study was approved by the University of Maryland Institutional Review Board and the
154 Human Research Protection Office of the Department of the Navy. Electronically signed
155 informed consent was obtained from all participants and questionnaire data were collected and
156 stored with REDCap [18].
157
Results
We enrolled 58 individuals with known close contact with an active COVID-19 case. Contacts
provided a total of 200 saliva and MTS pairs. The number of days of sample collection per
participant ranged from one to seven. Among the contacts, 14 (24%) had at least one positive
sample including 11 with both positive saliva and MTS samples over the course of follow-up.
One contact had only positive saliva on 3 out of 3 samples (on days -3, 0, and 1 post symptom
onset) and 2 had only positive MTS samples; one was positive on 2 of 2 swabs (on days 7 and
10) and one on 1 of 5 swabs (day 21, negative on days 14, 17, 19, and 24). Most of the positive
participants (92.9%) were symptomatic, whereas only one (2.3%) participant from the test
negative group reported symptoms. Symptomatic participants were enrolled -3 to 14 days since
symptom onset and gave samples for up to 24 days from onset of symptoms. Symptoms were
mild across the follow-up period. One participant had an oral temperature ≥ 38 °C at the time of
sampling; three in total had temperatures ≥ 37.8 °C, and six in total had temperatures ≥ 37.5 °C;
all were in the positive group. No other significant differences were identified between the
positive and negative groups (Table 1).
173
Viral RNA detection in and agreement between saliva and MTS
Among 200 pairs of saliva and MTS samples we detected viral RNA in 32 (16%) of the saliva
and 29 (14.5%) of the MTS samples. The frequency of detection was similar for both sample
types (p=0.781) (Table S1). Cohen's Kappa demonstrated substantial agreement (κ=0.83) with
26 (14%) positive and 165 (82.5%) negative sample pairs (Table 2). The 14 participants who
became positive by either sample type during the follow-up period provided 41 saliva-MTS
sample pairs, among which 71% of MTS and 78% of saliva samples were positive (Table S2),
without respect to time since symptom onset. When focusing on positive participants, however,
the agreement was weak (κ=0.43 for all and κ=0.42 for those who were symptomatic) (Table S3a
and S3b).
184
Comparison of Ct values between saliva and MTS
Each RT-PCR reaction contained 10 μL of heat-treated saliva sample or RNA extracted from
MTS. Assuming no loss in the process, each reaction represented 7.78 μL of saliva sample or 40
μL of the MTS eluate. The Ct values for paired samples were highly correlated (rho = 0.84, r2 =
0.74, Figure 1a). The Ct values for saliva were on average slightly but significantly greater than
for MTS samples (mean difference = 0.64, p=0.01) among all 58 participants (Figure 1b and
Figure S1), partially reflecting the difference in their input amounts.
192

193 *Relationship between days since symptom onset, sample types and probability of detection*
194 The Ct values among the positive symptomatic participants increased over time (day -3 through
195 24), indicating decreasing viral load. Saliva tended to have lower Ct values compared to MTS
196 from days -3 to 1.5, where MTS samples had lower Ct values thereafter (Figure 2A).
197
Among symptomatic participants who had one or more positive saliva or MTS samples, the
probability (sensitivity) of detecting viral RNA in saliva samples was 91% (10/11) from day -3
to day 2 (Table 3), was 89% (16/18) from day 3 through 8, and declined significantly thereafter
(Figure 2B and Figure S2). The probability of detecting virus in MTS samples from day -3
through day 2 was lower 45% (5/11), was 94% (17/18) from day 3 through 8, and then dropped
off again. Early in the course of infection (days -3 through 2) saliva had 12 times the odds of
being positive compared to MTS (Odds ratio = 12, 95% CI: 1.2, 130). Although there was a
trend toward greater sensitivity using MTS than saliva samples after day 2 post onset of
symptoms, the difference was not statistically significant (Table 3).
207
208 *Asymptomatic case*
209 Only one participant from our study population was an asymptomatic case. They provided one
210 pair of saliva and MTS samples, both of which were positive, with an average Ct value of 25.8
211 for MTS and 34.7 for saliva (Table S4).
212
213
Discussion
Early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal
swabs (MTS). We found that the optimal performance of saliva was in the pre-symptomatic
period and was more sensitive than MTS before symptom onset. Several studies have shown that
pre-symptomatic transmission plays a more important role than symptomatic and asymptomatic
transmission in the spread of SARS-CoV-2 [12,13]. Furthermore, saliva tended to have lower Ct
values compared to MTS from the pre-symptomatic period through the first few days post
symptom onset. Together, these findings suggest that saliva may be the preferred sample for
detecting SARS-CoV-2 early during the course of infection.
223
The CDC and the Infectious Disease Society of American recommendations for COVID-19
testing allow MTS, NPS, oral swabs, anterior nasal swabs, and saliva swabs as well as
saliva.[1,19] Some studies have shown differences in the sensitivity between NPS and MTS. In
older, more acutely ill populations, NPS appears to be more sensitive than MTS, especially later
in the course of illness (greater than 7 days) [4,9]. In a study of ambulatory and symptomatic
participants whose ages were more evenly distributed, NPS and MTS swabs were highly
correlated with a mean of 7 days since onset of symptoms [20]. Congrave-Wilson et al., in
agreement with the current study, found that saliva had the highest sensitivity in the first seven
days post COVID-19 onset when using NPS as the reference [2]. Becker et al. compared the
sensitivity of saliva and NPS for detecting COVID-19 in a convalescent cohort 8-56 days since
first symptom and found that NPS performed better [21]. They also showed that saliva was about
30% less sensitive than NPS in a diagnostic cohort, however, days since symptom onset were not
reported, so we cannot make direct comparison with our findings. Finally, a systematic review
by Bastos et al. found that saliva had similar sensitivity to NPS and costs less [11].
238

Our findings have implications for improving public acceptance of COVID-19 testing, reducing
the cost of mass COVID-19 screening, and improving the safety of healthcare workers who
conduct testing. These findings are extremely important when considering large-scale screening
of COVID-19 in schools and workplaces. In addition to its higher sensitivity in the early stage of
the disease as demonstrated in our data, saliva has quite a few other advantages that make it an
appealing screening tool. Saliva collection is less invasive and more acceptable to the general
population [7,22]. One of the barriers hindering COVID-19 testing is people's fear of nasal
swabs due to misinformation [23]. Also, the discomfort brought by nasal swabs may also reduce
people's willingness to get tested regularly, especially among children [24,25]. With the use of
saliva, screening in large groups with increased frequency may be more practicable. Saliva is
cheaper than swab-based methods, especially if pooled samples are used [11,26]. Bastos et al.
estimated that when sampling 100,000 individuals, using saliva saved more than $600,000 in
comparison to using NPS [11]. These cost savings are especially important in the context of low
resource settings.
253
Saliva collection is also safer for healthcare workers (HCWs). Amid the pandemic, one of the
key concerns among HCWs is the occupational exposure to SARS-CoV-2 aerosols during some
medical procedures [27]. The collection of nasal swabs introduces such exposure via the close
interaction between patients and HCWs and by patients' coughing and sneezing as a result of the
procedures [28]. In contrast, saliva is the only upper respiratory specimen suggested by the CDC
that can be self-collected without supervision [1] and hence protects HCWs from directly
contacting the patients when the samples are being collected. Given all these advantages of
saliva compared to NPS, our findings further support the use of saliva for large-scale screening,
especially of pre-symptomatic patients.
263
The current study has several limitations. The contacts enrolled in this study who eventually
tested positive for SARS-CoV-2 developed mild, and in some cases, transient infections. Some
of these mild (low viral titer) infections would not have been detected by less frequent testing
protocols and may not have posed a risk for onward transmission. The sample size of those who
tested positive is relatively small. Only one asymptomatic case was identified in our study so we
could not compare the sensitivity of the two types of samples among asymptomatic COVID-19
cases. The evidence for using saliva to detect asymptomatic cases was mixed in previous studies
[2,10] and further studies are needed to clarify this issue.
272
273   In conclusion, the use of saliva is preferable for testing pre-symptomatic populations. It is more
274   acceptable to people, which reduces barrier to testing. It is also more cost effective for
275   individuals to collect their own saliva rather than using highly trained professionals to collect
276   NPS and/or MTS. Finally, self-collected saliva samples eliminate the exposure to aerosols
277   produced by sneezing, coughing and gagging of patients undergoing NPS/MTS.
278
279

Funding
This work was supported by Prometheus-UMD, sponsored by the Defense Advanced Research
Projects Agency (DARPA) BTO under the auspices of Col. Matthew Hepburn through
agreement N66001-18-2-4015. This work was also supported by the National Institute of Allergy
and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (CEIRS)

Contract Number HHSN272201400008C, and the Centers for Disease Control and Prevention
Contract Number 200-2020-09528. The findings and conclusions in this report are those of the
authors and do not necessarily represent the official position or policy of these funding agencies
and no official endorsement should be inferred.
289
290   This work was also supported by a grant from the Bill & Melinda Gates Foundation, and a
291   generous gift from The Flu Lab (https://theflulab.org). The funders had no role in study design,
292   data collection, analysis, decision to publish, or preparation of the manuscript.
293
294   None of the authors have a potential conflicting interest or funding source.
295
Acknowledgements
We thank all the other members of the University of Maryland StopCOVID Research Group for
their efforts in recruiting participants and sample collection and processing: Oluwasanmi
Oladapo Adenaiye, Barbara Albert, P. Jacob Bueno de Mesquita, Yi Esparza, Aaron Kassman,
Michael Lutchenkov, Dewansh Rastogi, Maria Schanz, Isabel Sierra Maldonado, Aditya
Srikakulapu, Delwin Suraj, Faith Touré, Rhonda Washington-Lewis, Somayeh Youssefi, Stuart
Weston, Matthew Frieman, Mara Cai, Ashok Agrawala. We also thank Dr. Jamal Fadul and his
clinic in College Park, Maryland, for assistance in recruiting study participants.

References

1. Centers for Disease Control and Prevention. Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html. Accessed 12 October 2021.

2. Congrave-Wilson Z, Lee Y, Jumarang J, et al. Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection. JAMA **2021**; Available at: https://doi.org/10.1001/jama.2021.13967. Accessed 5 September 2021.

3. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic Review and Meta-analysis. Journal of Clinical Microbiology 59:e02881-20.

4. Jamal AJ, Mozafarihashjin M, Coomes E, et al. Sensitivity of midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infect Control Hosp Epidemiol :1–3.

5. Chu CY, Marais G, Opperman C, et al. Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa. Lancet Infect Dis **2021**; 21:1354.

6. Yp T, R J, B H, et al. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. The New England journal of medicine **2020**; 383. Available at: https://pubmed.ncbi.nlm.nih.gov/32492294/. Accessed 25 October 2021.

7. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-CoV-2 detection. The Lancet Respiratory Medicine **2021**; 9:562–564.

8. Vogels CBF, Watkins AE, Harden CA, et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med **2021**; 2:263-280.e6.

9. Pinninti S, Trieu C, Pati SK, et al. Comparing Nasopharyngeal and Mid-Turbinate Nasal Swab Testing for the Identification of SARS-CoV-2. Clin Infect Dis **2020**; Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337631/. Accessed 19 March 2021.

10. Teo AKJ, Choudhury Y, Tan IB, et al. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection. Scientific Reports **2021**; 11:3134.

11. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic Review and Meta-analysis. Ann Intern Med **2021**; 174:501–510.

12. Bender JK, Brandl M, Höhle M, Buchholz U, Zeitlmann N. Analysis of Asymptomatic and Presymptomatic Transmission in SARS-CoV-2 Outbreak, Germany, 2020. Emerg Infect Dis **2021**; 27. Available at: https://wwwnc.cdc.gov/eid/article/27/4/20-4576_article.htm. Accessed 8 October 2021.

13. Qiu X, Nergiz AI, Maraolo AE, Bogoch II, Low N, Cevik M. The role of asymptomatic and
pre-symptomatic infection in SARS-CoV-2 transmission—a living systematic review.
Clinical Microbiology and Infection **2021**; 27:511–519.

14. Adenaiye OO, Lai J, de Mesquita PJB, et al. Infectious SARS-CoV-2 in Exhaled Aerosols
and Efficacy of Masks During Early Mild Infection. Clin Infect Dis **2021**; :ciab797.

15. ThermoFisher Scientific. TaqPath^{TM} COVID-19 Combo Kit and TaqPath^{TM} COVID-19
Combo Kit Advanced* Instructions for Use. Available at:
https://www.fda.gov/media/136112/download. Accessed 24 November 2021.

16. Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods Med
Res **1995**; 4:187–196.

17. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria:
R Foundation for Statistical Computing, 2021. Available at: https://www.R-project.org/.

18. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
community of software platform partners. Journal of Biomedical Informatics **2019**;
95:103208.

19. Hanson KE, Caliendo AM, Arias CA, et al. The Infectious Diseases Society of America
Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. Clinical
Infectious Diseases **2021**; :ciab048.

20. Tu Y-P, Jennings R, Hart B, et al. Swabs Collected by Patients or Health Care Workers for
SARS-CoV-2 Testing. N Engl J Med **2020**; 383:494–496.

21. Becker D, Sandoval E, Amin A, et al. Saliva is less sensitive than nasopharyngeal swabs for
COVID-19 detection in the community setting. medRxiv **2020**; :2020.05.11.20092338.

22. Byrne RL, Kay GA, Kontogianni K, et al. Saliva offers a sensitive, specific and non-invasive
alternative to upper respiratory swabs for SARS-CoV-2 diagnosis. medRxiv
2020; :2020.07.09.20149534.

23. Yangchen S, Ha S, Assan A, Tobgay T. Factors Influencing COVID-19 Testing: A
Qualitative Study in Bhutan. In Review, 2021. Available at:
https://www.researchsquare.com/article/rs-885659/v1. Accessed 9 November 2021.

24. Clifford V, Curtis N. Saliva testing for severe acute respiratory syndrome coronavirus 2 in
children. Clinical Microbiology and Infection **2021**; 27:1199–1201.

25. Leach AJ, Stubbs E, Hare K, Beissbarth J, Morris PS. Comparison of Nasal Swabs with
Nose Blowing for Community-Based Pneumococcal Surveillance of Healthy Children.
Journal of Clinical Microbiology **2008**; 46:2081–2082.

26. Watkins AE, Fenichel EP, Weinberger DM, et al. Increased SARS-CoV-2 Testing Capacity
with Pooled Saliva Samples. Emerg Infect Dis **2021**; 27.

27. Nicholson PJ, Sen D. Healthcare workers and protection against inhalable SARS-CoV-2
aerosols. Occupational Medicine **2021**; 71:118–120.

28. Qian Y, Zeng T, Wang H, et al. Safety management of nasopharyngeal specimen collection
from suspected cases of coronavirus disease 2019. Int J Nurs Sci **2020**; 7:153–156.

385
386

387 Tables
388
389 Table 1. Characteristics of the study population

		Never positive	Positive for MTS or saliva	All participants
Number of participants		44	14	58
Number of sample pairs		159	41	200
Number of days of sample collection per participant, median (range)		4 (1, 7)	3 (1, 6)	3 (1, 7)
Female, N (%)		20 (46)	8 (57)	28 (48)
Age, mean ± SD		26.5 ± 15.5	27.3 ± 13.8	26.7 ± 15
Age group, N (%)				
<18		2 (4)	1 (7)	3 (5)
18-45		38 (86)	11 (79)	49 (84)
>45		4 (9)	2 (14)	6 (10)
White, N (%)		30 (68)	11 (79)	41 (71)
BMI, mean ± SD		25.6 ± 4.9	25.2 ± 4.4	25.5 ± 4.7
Chronic respiratory illness [a], N (%)		17 (39)	5 (36)	22 (38)
Ever smoker, N (%)		1 (2)	1 (7)	2 (3)
Ever symptomatic [b], N (%)		1 (2)	13 (93)	14 (24)
Symptomatic participants	Days since symptom onset at enrollment, median (range)	2 (-)	3 (-3, 14)	2.5 (-3, 14)
	Overall days since symptom onset of sample collection, median (range)	6.5 (2, 12)	5 (-3, 24)	5 (-3, 24)
	Loss of taste/smell, N (%)	0	2 (15)	2 (14)
	Median upper [c] respiratory symptoms (IQR)	3 (1.2, 6.2)	2 (0, 3)	2 (0.2, 3)
	Median lower respiratory symptoms (IQR)	0 (0, 0)	0 (0, 1)	0 (0, 1)
	Median systemic symptoms (IQR)	0.5 (0, 1.8)	0 (0, 1.2)	0 (0, 1.8)
	Median gastrointestinal symptoms (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 0)
	Temperature, mean Celsius ± SD	37 ± 0.3	37.2 ± 0.5	37.2 ± 0.4

[a] Chronic respiratory illness = volunteers with any Chronic obstructive pulmonary disease,
Asthma, Other lung diseases.
[b] Group comparison, p<0.05.

[c] Symptoms at the time of each sample collection visit. Sixteen individual symptoms were rated
from 0 to 3. Systemic (max score of 12) = malaise + headache + muscle/joint ache +
sweats/fever/chills; Gastrointestinal (max score of 12) = loss of appetite + nausea + vomit +
diarrhea; Lower Respiratory (max score of 9) = chest tightness + shortness of breath + cough;
Upper Respiratory (max score of 15) = runny nose + stuffy nose + sneeze + earache + sore
throat.
399

400
401

402 Table 2. Viral RNA detection in paired saliva and MTS samples from all participants (N=58) [a]

Saliva Positive	MTS Positive		Total
	No	Yes	
No	165	3	168
Yes	6	26	32
Total	171	29	200

403 [a] κ=0.83

405   Table 3. Sensitivity of saliva and MTS and relative odds of detection of SARS-CoV-2 in saliva
406   by day since symptom onset among 13 mildly symptomatic contacts of known cases

Days since symptom onset [a]	Saliva Positive/N (Sensitivity %)	MTS Positive/N (Sensitivity %)	Odds Ratio Saliva:MTS	p-value
-3 through 2	10/11 (91)	5/11 (45)	12 (1.2, 130)	0.04
3 through 8	16/18 (89)	17/18 (94)	0.47 (0.037, 6)	0.55
9 through 24	5/11 (45)	6/11 (55)	0.7 (0.13, 3.8)	0.67

407   [a] Days since symptom onset inclusive of the start and end day

 Figure Legends
410

Figure 1. Association between Ct values of saliva and MTS samples among 58 participants and
400 samples
A. Scatter plot of Ct values of saliva and MTS
B. Bland-Altman plot for comparison of saliva and MTS

Figure 2. The change of Ct values and probability of testing positive by days since symptom
onset. Data are for MTS and saliva samples from 13 participants who provided a total of 40 pairs
of samples and had one or more samples positive for SARS-CoV-2 RNA.
A. Change of Ct values by days since symptom onset,
B. Probability of being tested positive by days since symptom onset estimated from a generalized
additive logistic model.
422
423
424

425
426

427 Figures
428